December 14, 2012

Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO™ (mipomersen)

 

Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO™ (mipomersen)

Cambridge, Mass. and Carlsbad, Calif., Dec. 14, 2012 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for its marketing authorization application (MAA) for KYNAMROTM (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolaemia (HoFH). Genzyme plans to request a re-examination of the CHMP Opinion.